Current study data, published in Women’s Health Journalsuggested the promise of Ibrexafungerp for the treatment of vulvovaginal candidiasis, or yeast infection.
Ibrexafungerp is a novel oral antifungal drug developed by biotechnology company Scynexis, Inc.
To understand the significance of these study results and the need for new treatments for yeast infections, infection interviewed Tosin Jaiyeoba Goje, MD, MSCR, FACOG. Goje is Medical Director of the Cleveland Clinic Center for Infant and Maternal Health and Associate Professor of Gynecology and Reproductive Biology at the Cleveland Clinic Lerner College of Medicine.
Goje emphasized that fungal infections can severely affect patients’ everyday lives. In particular, she pointed out the psychosocial, sexual, and financial implications of yeast infection. “Overall, it just affects their quality of life,” Goje said, “and I think a person’s quality of life is important.”
Goje said that there is a significant shortage of medicines for women’s health, especially compared to other specialties.
These positive data for ibrexafungerp result from 2 different stage 3 clinical studies. The pooled analysis of these randomized, double-blind, multi-centre, placebo-controlled studies revealed that the patients who received ibrexafungerp had significantly higher rates of clinical improvement, complete symptom resolution and mycological cure .
Study patients ranged in age from 12 to 80 years and represented a variety of races, ethnicities and body mass index (BMI). Participants were excluded if they had an otherwise immunocompromised condition.
Ibrexafungerp was found to be safe and tolerable, and most reported side effects were gastrointestinal.
“It’s important that race doesn’t affect the drug,” Goje said. “Anyone of all races and ethnicities can benefit from the drug. Additionally, “BMI had no adverse effects.”
Returning to her point that vaginal candidiasis affects quality of life, Goje concluded, “We want to have medicines that are not only effective, but for all people.”